KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) Equity Average (2016 - 2025)

Historic Equity Average for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $53.2 million.

  • Travere Therapeutics' Equity Average rose 79452.54% to $53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.2 million, marking a year-over-year increase of 79452.54%. This contributed to the annual value of $129.9 million for FY2024, which is 665.93% up from last year.
  • Latest data reveals that Travere Therapeutics reported Equity Average of $53.2 million as of Q3 2025, which was up 79452.54% from $32.8 million recorded in Q2 2025.
  • Over the past 5 years, Travere Therapeutics' Equity Average peaked at $347.5 million during Q2 2021, and registered a low of -$7.7 million during Q3 2024.
  • Its 5-year average for Equity Average is $153.9 million, with a median of $137.4 million in 2024.
  • As far as peak fluctuations go, Travere Therapeutics' Equity Average tumbled by 10386.3% in 2024, and later soared by 79452.54% in 2025.
  • Travere Therapeutics' Equity Average (Quarter) stood at $304.7 million in 2021, then tumbled by 76.45% to $71.8 million in 2022, then surged by 234.83% to $240.3 million in 2023, then crashed by 94.04% to $14.3 million in 2024, then soared by 271.42% to $53.2 million in 2025.
  • Its last three reported values are $53.2 million in Q3 2025, $32.8 million for Q2 2025, and $45.9 million during Q1 2025.